Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Patent Interference
29 janv. 2014 17h01 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 29, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix to Raise $106.7 Million Through Registered Direct Offering
28 janv. 2014 08h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir
13 janv. 2014 07h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
07 janv. 2014 08h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 32nd Annual J.P. Morgan...
Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
06 janv. 2014 08h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Declaration of Senior Party in a Second Patent Interference by the USPTO
09 déc. 2013 08h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Initiation of Enrollment in a Phase II All-Oral Combination Study of Samatasvir (IDX719), Simeprevir, and TMC647055 for the Treatment of Hepatitis C Virus (HCV) Infection
02 déc. 2013 07h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences
02 déc. 2013 07h00 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
25 nov. 2013 16h05 HE
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Nov. 25, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will participate in a fireside chat discussion at the 2013...
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2013 Financial Results and Provides HCV Pipeline Update
30 oct. 2013 16h05 HE
|
Idenix Pharmaceuticals
-- Enrollment initiated for a phase I/II clinical trial for IDX21437, a next-generation uridine nucleotide prodrug inhibitor for the treatment of hepatitis C virus infection (HCV)
-- Initiation...